Bryan Mazlish

Bigfoot Biomedical is a new kind of medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes. With an intense focus on ease of use, Bigfoot will optimize the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. The company’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. Bigfoot will be the first company to deliver a monthly subscription-based service leveraging a smart, connected insulin dosing platform to meet the needs of a diverse population with insulin-requiring diabetes. Bigfoot’s investigational system is comprised of best-in-class proprietary and licensed components holistically and securely integrated, leveraging intuitive design, machine learning, and a mobile app running on an off-the-shelf smartphone, all designed to keep glucose levels in an optimal range. “The net result is a company that brings something unique to the table: a remarkable depth of knowledge and technical know-how combined with the personal motivation and direct patient experience necessary to really make a difference in this space.” ---The MedTech Strategist, October 24, 2016

Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel Lab. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. For more information about Surf Bio, visit www.surf.bio.

Bigfoot Biomedical is a new kind of medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes. With an intense focus on ease of use, Bigfoot will optimize the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. The company’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. Bigfoot will be the first company to deliver a monthly subscription-based service leveraging a smart, connected insulin dosing platform to meet the needs of a diverse population with insulin-requiring diabetes. Bigfoot’s investigational system is comprised of best-in-class proprietary and licensed components holistically and securely integrated, leveraging intuitive design, machine learning, and a mobile app running on an off-the-shelf smartphone, all designed to keep glucose levels in an optimal range. “The net result is a company that brings something unique to the table: a remarkable depth of knowledge and technical know-how combined with the personal motivation and direct patient experience necessary to really make a difference in this space.” ---The MedTech Strategist, October 24, 2016

Citis mission is to serve as a trusted partner to our clients by responsibly providing financial services that enable growth and economic progress. Our core activities are safeguarding assets, lending money, making payments and accessing the capital markets on behalf of our clients. We have over 200 years of experience helping our clients meet the worlds toughest challenges and embrace its greatest opportunities. We are Citi, the global bank – an institution connecting millions of people across hundreds of countries and cities. For information on Citi’s commitment to privacy, visit on.citi/privacy.